Dexmedetomidine
Osteoarthritis, Hip
Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Poznan University of Medical Sciences
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07327931CT.gov PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults | — | Recruiting | — | — | — |
NCT06233604CT.gov Dexamethasone vs. Dexmedetomidine for ESPB in Pain Management After Hip Arthroplasty | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteoarthritis, Hip
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexmedetomidine (this asset) | Poznan University of Medical Sciences | Approved | BB · 65 |
| Ropivacaine | Poznan University of Medical Sciences | P4 | BBB |
| Dexasone | Poznan University of Medical Sciences | P4 | BBB |
| Celecoxib | Pfizer | P4 | BB |
| Intravenous Dexamethsone | Poznan University of Medical Sciences | P4 | BB |
| Remimazolam | Seoul National University Hospital | P4 | BB |
| Oxycodone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P3 | BB |
| Tranexamic Acid | Konkuk University Medical Center | P4 | BB |
| cov155 | Mallinckrodt | P3 | BB |
+7 more in the Osteoarthritis, Hip cohort
Other indications for Dexmedetomidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizophreniform Disorder | — | P4 | A · 80 |
| Schizoaffective Disorder | — | P4 | BBB · 77 |
| Neuralgia | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Dexmedetomidine in Osteoarthritis, Hip. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/dexmedetomidine-osteoarthritis-hip
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →